Ellison Suthoff

735 total citations · 1 hit paper
35 papers, 466 citations indexed

About

Ellison Suthoff is a scholar working on Pulmonary and Respiratory Medicine, Pharmacology and Social Psychology. According to data from OpenAlex, Ellison Suthoff has authored 35 papers receiving a total of 466 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 8 papers in Pharmacology and 7 papers in Social Psychology. Recurrent topics in Ellison Suthoff's work include Cystic Fibrosis Research Advances (13 papers), Treatment of Major Depression (8 papers) and Mental Health Treatment and Access (5 papers). Ellison Suthoff is often cited by papers focused on Cystic Fibrosis Research Advances (13 papers), Treatment of Major Depression (8 papers) and Mental Health Treatment and Access (5 papers). Ellison Suthoff collaborates with scholars based in United States, United Kingdom and Ireland. Ellison Suthoff's co-authors include Brian Werneburg, Alexandra L. Quittner, Mei Sheng Duh, Caroline Korves, Ken Duckworth, Mark Kosinski, Izabela Aleksanderek, Ronald C. Kessler, Shih‐Yin Chen and G. Dennis and has published in prestigious journals such as Biological Psychiatry, American Journal of Obstetrics and Gynecology and The Journal of Pediatrics.

In The Last Decade

Ellison Suthoff

33 papers receiving 454 citations

Hit Papers

The Economic Burden of Adults with Major Depressive Disor... 2023 2026 2024 2025 2023 20 40 60
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Economic Burden of Adults with Major Depressive Disorder in the United States (2019)
    2023 70 citations RN, A.S. Chitnis et al. Advances in Therapy profile →

Peers

Ellison Suthoff
Rose Maxwell United States
Erin Kelly Canada
Yuanyuan Qu China
Hui Han China
Lauren Clevenger United States
Jeanne Walter United States
Andrew H. Miller United States
Andrew Crawford United Kingdom
Eli Iacob United States
Basil G. Bereza Canada
Rose Maxwell United States
Ellison Suthoff
Citations per year, relative to Ellison Suthoff Ellison Suthoff (= 1×) peers Rose Maxwell

Countries citing papers authored by Ellison Suthoff

Since Specialization
Citations

This map shows the geographic impact of Ellison Suthoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellison Suthoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellison Suthoff more than expected).

Fields of papers citing papers by Ellison Suthoff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellison Suthoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellison Suthoff. The network helps show where Ellison Suthoff may publish in the future.

Co-authorship network of co-authors of Ellison Suthoff

This figure shows the co-authorship network connecting the top 25 collaborators of Ellison Suthoff. A scholar is included among the top collaborators of Ellison Suthoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellison Suthoff. Ellison Suthoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
RN, A.S. Chitnis, Derek Louie, et al.. (2023). The Economic Burden of Adults with Major Depressive Disorder in the United States (2019). Advances in Therapy. 40(10). 4460–4479. 70 indexed citations breakdown →
4.
Duckworth, Ken, et al.. (2022). Impact of Major Depressive Disorder on Comorbidities. The Journal of Clinical Psychiatry. 83(6). 71 indexed citations
5.
Zhu, Ling, et al.. (2022). Economic burden and antidepressant treatment patterns among patients with major depressive disorder in the United States. Journal of Managed Care & Specialty Pharmacy. 28(11-a Suppl). S2–S13. 5 indexed citations
6.
Suthoff, Ellison, Mark Kosinski, Paul Hodgkins, et al.. (2022). Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder. Journal of Affective Disorders. 308. 19–26. 19 indexed citations
7.
Gupta, Shaloo, et al.. (2022). Humanistic and economic burden associated with depression in the United States: a cross-sectional survey analysis. BMC Psychiatry. 22(1). 542–542. 29 indexed citations
8.
Suthoff, Ellison, Brian Werneburg, Paul Hodgkins, et al.. (2021). Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder. Journal of Affective Disorders. 285. 112–119. 16 indexed citations
9.
Suthoff, Ellison, et al.. (2021). The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder. PharmacoEconomics. 39(6). 691–706. 10 indexed citations
10.
Suthoff, Ellison, et al.. (2020). PMH32 Development of a Microsimulation Model to Evaluate the Clinical Burden of Major Depressive Episodes. Value in Health. 23. S589–S590. 1 indexed citations
11.
McCarrier, Kelly P., Mariam Hassan, Paul Hodgkins, et al.. (2020). The Cystic Fibrosis Impact Questionnaire: qualitative development and cognitive evaluation of a new patient-reported outcome instrument to assess the life impacts of cystic fibrosis. Journal of Patient-Reported Outcomes. 4(1). 36–36. 7 indexed citations
12.
Suthoff, Ellison, Jochen G. Mainz, D. Cox, et al.. (2019). Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis. The Journal of Pediatrics. 215. 164–171.e2. 13 indexed citations
13.
Bonthapally, Vijayveer, Handan Gunduz-Bruce, Christopher Silber, et al.. (2019). Health-related quality of life in a Phase 2, randomized, placebo-controlled trial of the GABA(A)R modulator SAGE-217 in major depressive disorder. European Neuropsychopharmacology. 29. S58–S58. 1 indexed citations
14.
Flume, Patrick A., Ellison Suthoff, Mark Kosinski, Gautham Marigowda, & Alexandra L. Quittner. (2018). Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis. Journal of Cystic Fibrosis. 18(5). 737–742. 28 indexed citations
15.
16.
Quittner, Alexandra L., Ellison Suthoff, Regina Rendas‐Baum, et al.. (2015). Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes. 13(1). 93–93. 32 indexed citations
17.
Yarlas, Aaron, et al.. (2015). Measuring Generic Health-Related Quality Of Life And Impact Of Health Resource Utilization In Adults With Cystic Fibrosis. Value in Health. 18(7). A503–A503. 1 indexed citations
18.
Oglesby, Alan, Caroline Korves, François Laliberté, et al.. (2014). Impact of Early Versus Late Systemic Lupus Erythematosus Diagnosis on Clinical and Economic Outcomes. Applied Health Economics and Health Policy. 12(2). 179–190. 72 indexed citations
19.
Castellano, Daniel, Mei Sheng Duh, Caroline Korves, et al.. (2013). Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain. Expert Opinion on Drug Safety. 12(4). 455–463. 4 indexed citations
20.
Oglesby, AK, G. Dennis, Caroline Korves, et al.. (2012). PSY56 Impact of Early Versus Late Systemic Lupus Erythematosus (SLE) Diagnosis on Clinical and Economic Outcomes. Value in Health. 15(4). A109–A109. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rose Maxwell Breakdown of academic impact, for papers by Erin Kelly Breakdown of academic impact, for papers by Yuanyuan Qu Breakdown of academic impact, for papers by Hui Han Breakdown of academic impact, for papers by Lauren Clevenger Breakdown of academic impact, for papers by Jeanne Walter Breakdown of academic impact, for papers by Andrew H. Miller Breakdown of academic impact, for papers by Andrew Crawford Breakdown of academic impact, for papers by Eli Iacob Breakdown of academic impact, for papers by Basil G. Bereza
Rankless by CCL
2026